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Summary.
Inverse probability weighting is increasingly used in causal inference, but the g-computation
constitutes a promising alternative. We aimed to compare the performances of these
methods with time-to-event outcomes. Given the limitations of the interpretability of the
hazard ratio for causal inference, our target estimand of interest is the difference in re-
stricted mean survival times. We report the findings of an extensive simulation study,
showing that both inverse probability weighting and g-computation were unbiased under
a correct model specification, but g-computation was generally more efficient. We also
analyse two real-life datasets to illustrate these results. We update the R package RISCA
to facilitate the implementation of g-computation.
Keywords: causal inference, g-computation, inverse probability weighting, restricted
mean survival time, simulation study, time-to-event outcomes.
1. Introduction
Real-world evidence means scientific evidence obtained from data collected outside the
context of randomised clinical trials (Sherman et al., 2016). The absence of randomisa-
tion complicates the estimation of the marginal causal effect (hereafter referred merely
as causal effect) of exposure (including treatment or intervention) due to a potential risk
of confounding (Herna´n, 2004). Rosenbaum and Rubin (1983) introduced the propen-
sity score (PS) as a tool for causal inference in the presence of measured confounders.
ar
X
iv
:2
00
6.
16
85
9v
1 
 [s
tat
.M
E]
  3
0 J
un
 20
20
2 Chatton et al.
In a binary exposure setting, it has been shown that the estimated PS is a balancing
score, meaning that conditionally on the estimated PS, the distribution of covariates is
similar between exposed and unexposed patients. Following this property, the PS can
be used in four different ways to provide estimates of the causal exposure effect: match-
ing, stratification, adjustment, and inverse probability weighting (IPW, Robins et al.,
2000). Stratification leads to residual confounding (Lunceford and Davidian, 2004) and
adjustment relies on stronger modelling assumptions (Vansteelandt and Daniel, 2014).
Although matching on PS has always been the most popular (Ali et al., 2015), IPW
appears to be less biased and more precise in several studies (Le Borgne et al., 2016;
Hajage et al., 2016; Austin, 2013). Moreover, King and Nielsen (2019) argued for halting
the use of PS matching for many reasons such as covariate imbalance, inefficiency, model
dependence, and bias.
Causal effects can also be estimated using the G-computation (GC), a maximum
likelihood substitution estimator of the g-formula (Snowden et al., 2011; Keil et al.,
2014). While IPW rests on the exposure modelling, the GC relies on the prediction
of the potential outcomes for each subject under each exposure status. Robins (1986)
proposed the GC to estimate causal effects in the presence of time-varying confounders.
Several studies (see Chatton et al., 2020, and references inside) compared the IPW and
the GC in different contexts. They reported a lower variance for the GC than the IPW.
Nevertheless, to the best of our knowledge, no study focused on time-to-event outcomes.
The presence of right-censoring and its magnitude is of prime importance since a small
number of observed events due to censoring may impact the estimation of the outcome
model involved in the GC. Contrariwise, the IPW may have good performance as long as
the number of exposed patients is sufficient to estimate the PS and the total sample size
large enough to limit variability in the estimated weights. Besides the lack of simulation-
based studies comparing the GC and the IPW in a time-to-event context, the GC-based
estimates, such as hazard ratio or restricted mean survival, are not straightforward to
obtain. Time-to-event outcomes result in methodological difficulties, mainly due to the
time-varying distribution of individual baseline characteristics.
In the present paper, we aimed to detail the statistical framework for using the GC
in time-to-event analyses. We restricted our developments to time-invariant confounders
because the joint modelling of time-to-event and longitudinal data requires for controlling
the time-varying confounding by GC or IPW (Herna´n et al., 2001) is beyond the scope of
this paper. We also compared the performances of the GC versus the IPW. The paper is
structured as follows. In section 2, we detailed the methods. Section 3 presents the design
and findings of a simulation study. In section 4, we proposed a practical comparison
with two real-world applications related to treatment evaluations in multiple sclerosis
and kidney transplantation. Finally, we discussed the results and provided practical
recommendations to help analysts to choose the appropriate analysis method.
2. Methods
2.1. Notations
Let (Ti, δi, Ai, Li) be the random variables associated with the subject i (i = 1, ..., n). n
is the sample size, Ti is the participating time, δi is the censoring indicator (0 if right-
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censoring and 1 otherwise), Ai is a binary time-invariant exposure initiated at time T = 0
(1 for exposed subjects and 0 otherwise), and Li = (L1i, ..., Lpi) is the vector of the p
measured time-invariant confounders. Let Sa(t) be the survival function of the group
A = a at time t, and λa(t) the corresponding instantaneous hazard function. Suppose
Da the number of different observed times of event in the group A = a. At a time tj
(j = 1, ..., Da), the number of events dja and the number of at-risk subjects Yja in the
group A = a can be defined as dja =
∑
i:ti=tj
δi1(Ai = a) and Yja =
∑
i:ti≥tj 1(Ai = a).
2.2. Estimands
The hazard ratio (HR) has become the estimand of choice to confounder-adjusted studies
with time-to-event outcomes. However, it has also been contested (Herna´n, 2010; Aalen
et al., 2015), mainly because the baseline distribution of confounders varies over time.
For instance, consider a population in which there is no confounder at baseline, i.e., the
distribution of L is identical regardless of the exposure’s level A. Suppose additionally
that the quantitative covariate L1 and the exposure A are independently associated
with a higher risk of death. In this situation, as illustrated in Figure 1, the difference
between the L1 mean values of the two groups increases over time. Then, even when the
subject-specific proportional hazard (PH) assumption is true, i.e., the HR between an
exposed and an unexposed patient with the same characteristics L is constant over the
time, the population-average HR may vary over the time. Instead of the HR, one can
estimate an average over the time of the different time-specific HRs (Schemper et al.,
2009): AHR =
∫
[λ1(t)/λ0(t)]f(t).
Nevertheless, Aalen et al. (2015) concluded that it is still difficult to draw causal
conclusions from such a relative estimand. Herna´n (2010) advocated for the use of
the adjusted survival curves and related differences. For instance, the restricted mean
survival time (RMST) allows us to summarise a survival curve for a specific time-window
(Royston and Parmar, 2013) and compare two curves by looking at the difference in
RMST. The RMST difference up to time τ is formally defined as :
∆(τ) =
∫ τ
0
[S1(t)− S0(t)]dt (1)
It corresponds to the difference in terms of mean event-free time between two groups
of exposed and unexposed individuals followed-up to time τ . A further advantage of the
RMST difference is its usefulness for public health decision-making (Poole, 2010). Note
that other alternatives exist, such as the attributable fraction or the number needed to
treat (Sjo¨lander, 2018), that might dodge this problematic.
Hereafter, we considered AHR and ∆(τ).
2.3. Weighting on the inverse of propensity score
Formally, the PS is pi = P (Ai = 1|Li), i.e., the probability for the subject i to be
exposed according to her/his characteristics Li. In practice, analysts often used the
logistic regression. Let ωi be the weight of the subject i. Xu et al. (2010) defined
ωi = AiP (Ai = 1)/pi + (1 − Ai)P (Ai = 0)/(1 − pi), allowing to obtain a pseudo-
population in which the distribution of covariates is balanced between exposure groups,
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enabling to estimate the causal effect in the entire population (Herna´n, 2004). The use
of stabilised weights has been shown to produce a suitable estimate of the variance even
when there are subjects with extremely large weights (Robins et al., 2000; Xu et al.,
2010). The weighted number of events and at-risk subjects at time tj in the group
A = a are dωja =
∑
i:ti=tj
ωiδi1(Ai = a) and Y
ω
ja =
∑
i:ti≥tj ωi1(Ai = a), respectively.
Cole and Herna´n (2004) proposed a weighted Kaplan-Meier estimator defined as :
Sˆa(t) =
∏
tj≤t
[
1− dωja/Y ωja
]
(2)
To estimate the corresponding AHR, they also suggested the use of a weighted uni-
variate Cox PH model, in which the exposure is the single explanatory variable. We use
the equation (1) to estimate the corresponding ∆(τ).
2.4. G-computation
Akin to the IPW, the GC involves two steps. The first one consists in estimating the
outcome model, called the Q-model (Snowden et al., 2011). When suitable, it can consist
in a PH regression: h(t|Ai, Li) = h0(t) exp(γAi+βLi) where h(t|Ai, Li) is the conditional
hazard function of the subject i at time t, h0(t) the baseline hazard function, and γ and
β the regression coefficients. The estimations of the cumulative baseline hazard Hˆ0(t)
and the regression coefficients (γˆ, βˆ) can be obtained by the joint likelihood proposed by
Breslow (1972). The second step consists in predicting the counterfactual mean survival
function if all subjects would have been exposed (do(A = 1)) or unexposed (do(A = 0)):
Sˆa(t) = n
−1
n∑
i=1
exp
[
− Hˆ0(t)× exp(γˆ × do(Ai = a) + βˆLi)
]
(3)
Afterwards, ÂHR could be computed by the mean of the individual counterfactual
hazard ratios at the observed event times (Schemper et al., 2009):
ÂHR =
[ n∑
i=1
δi
]−1 n∑
i=1
δi
[
λˆ1(ti)/λˆ0(ti)
]
, (4)
where λˆa(t) = −∂ log Sˆa(t)/∂t, which is obtained from the equation (3) by numerical
differentiation. We use the equation (1) to estimate the corresponding ∆(τ).
2.5. Software
We performed all the analyses using R version 3.6.0. (R Core Team, 2014). To facilitate
their use in practice, we have implemented the previous methods in the R package
entitled RISCA (versions ≥ 0.8.1), which is available at cran.r-project.org. We obtained
the variances by bootstrap, as recently recommended by Austin (2016).
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2.6. Identifiability conditions
As for standard regression models, the IPW and the GC require the assumptions of no
measurement error, no model misspecification, and no interference (Hudgens and Hallo-
ran, 2008). Three additional assumptions, called identifiability conditions, are necessary
for causal inference (Naimi et al., 2016). (a) The values of exposure under compar-
isons correspond to well-defined interventions that, in turn, correspond to the versions
of exposure in the data. (b) The conditional probability of receiving every value of
exposure depends only on the measured covariates. (c) The conditional probability of
receiving every value of exposure is greater than zero. These assumptions were known
as consistency, conditional exchangeability and positivity, respectively.
3. Simulations study
3.1. Data generation
We generated the data in three steps. (a) We simulated three covariates (L1 to L3)
from a Bernoulli distribution with parameter equal to 0.5 and three covariates (L4 to
L6) from a standard normal distribution (Figure 2). (b) We generated the exposure A
according to a Bernoulli distribution with probability obtained by the logistic model with
the following linear predictor: −0.5+log(2) ·L2 +log(1.5)L3 +log(1.5)L5 +log(2)L6. We
set the intercept to obtain a prevalence of exposed individuals at 50%. (c) We generated
the times-to-event from a Weibull PH model. We set the scale and shape parameters
to 40.0 and 2.0, respectively. Based on a random variable Ui drawn from a standard
uniform distribution, we then computed the time-to-event from a Weibull PH model as
40.0 ∗ [(1− log(1−Ui) exp(−γAi− log(1.8)L1− log(1.3)L2− log(1.8)L4− log(1.3)L5))−
1]−2.0, where γ = log(1.0) under the null hypothesis or log(1.3) under the alternative
one. We subsequently censored the times-to-event using a uniform distribution on [0,70]
or [0,15], leading to approximately 40% and 90% censored observations, respectively.
We explored three sample sizes: n = 100, 500, or 2000. When the censoring rate
was 90%, we did not investigate the smallest sample size due to the reduced number
of events. For each scenario, we randomly generated 10,000 datasets. To compute the
difference of ∆(τ), we defined τ in each dataset as the time where at least 10% of the
individuals in each group (exposed or unexposed) were still at-risk.
We furthermore investigated the consideration of two sets of covariates: (L1, L2, L4, L5)
the risk factors of the outcome, or (L2, L5) the true confounders.
3.2. Performance criteria
We computed the theoretical values of the AHR and ∆(τ) by averaging the estima-
tions, respectively obtained from univariate Cox PH models (A as the only explanatory
covariate) and by the equation (1) where the survival functions have been estimated
by the Kaplan-Meier estimator, fitted from datasets simulated as above, except that A
was simulated independently of L (Gayat et al., 2012). We reported the following cri-
teria: (a) the percentage of datasets without convergence ; (b) the mean absolute bias:
MAB = E(θˆ)−θ, where θ is the estimand of interest ; (c) the mean square error: MSE =
E[(θˆ − θ)2] ; (d) the variance estimation bias: V EB = 100 × (E[ŜD(θˆ)]/SD(θˆ) − 1),
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where ŜD(•) is the asymptotic standard deviation and SD(•) the empirical standard
deviation ; (e) the empirical coverage rate of the nominal 95% confidence interval (CI),
defined as the percentage of 95% CIs including θ ; (f) the type I error, defined as the
percentage of rejection of the null hypothesis under the null hypothesis ; and (g) the
statistical power, defined as the percentage of rejections of the null hypothesis under
the alternative hypothesis. We computed the Monte Carlo standard errors for each
performance measure (Morris et al., 2019).
3.3. Results
The Monte Carlo errors were very weak. We have not encountered any convergence
problems. Figures 3 and 4 present the results under the alternative hypotheses for AHR
and ∆, respectively. The results under the null hypothesis were comparable and can be
found in supplementary materials available online.
The MAB associated with IPW and GC were similar to zero in all scenarios, regard-
less of the considered covariates set (all the risk factors or only the true confounders).
Nevertheless, the MAB under the alternative hypothesis was slightly lower with the
GC when considering all the risk factors. For instance, in terms of ∆ when n = 500
and a censoring rate at 40%, the MAB was 0.033 for GC versus 0.061 for IPW. When
considering the true confounders, these values were 0.147 versus 0.066, respectively.
The GC, when considering all the outcome causes, resulted in the best results in
terms of MSE, especially for small sample sizes. For instance, when n = 100 and a
censoring rate at 40%, the MSE related to the AHR was 0.056 for GC versus 0.068
for IPW. When considering the true confounders, these values were 0.076 versus 0.079,
respectively.
Regarding the VEB, the results were close between the GC and the IPW. One can
nevertheless note lower values for the IPW when n = 100 and estimating the AHR. For
instance, when the censoring rate was 40%, the VEB values were in-between 4.1% and
4.7% for GC, versus 2.4% and 3.7% for IPW.
All scenarios broadly respected the nominal coverage value of 95%. The power was
the highest for the GC, especially when considering all the risk factors, with a gain
in-between 10% and 13%.
With a censoring rate at 90%, the two methods led to close results, irrespective of
the considered covariates.
4. Applications
We used the data from two studies performed by Laplaud et al. (2019) in multiple scle-
rosis and Masset et al. (2019) in kidney transplantation. We conducted these studies
following the French law relative to clinical noninterventional research. Written in-
formed consents were collected. Moreover, the French commission for data protection
approved the collection (CNIL decisions DR-2014-327 and 914184, respectively). To
guide variable selection, we asked experts which covariates were causes of the exposure
or the outcome prognosis to define the causal structure, as proposed by VanderWeele
and Shpitser (2011). We checked the positivity assumption and the considered covariates
balance (see supplementary materials available online). The log-linearity hypothesis of
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continuous covariates has been verified in the univariate analysis if the Bayesian infor-
mation criterion (Schwart, 1978) was not reduced using natural spline transformation
compared to the inclusion of the covariate in its natural scale. In case of violation,
we used a natural spline transformation. We also assessed the PH assumption by the
Grambsch-Therneau test at a significance level of 5% (Grambsch and Therneau, 1994).
For simplicity, we performed complete case analyses.
4.1. Dimethylfumarate versus Teriflunomide to prevent the relapse in multiple sclero-
sis
With the increasing number of available drugs for preventing relapses in multiple sclerosis
and the lack of head-to-head randomised clinical trials, Laplaud et al. (2019) aimed
to compare Teriflunomide (TRF) and Dimethylfumarate (DMF) using data from the
multicentric cohort OFSEP. We reanalysed the primary outcome, defined as the time-
to-first relapse. We presented the cohort characteristics of 1770 included patients in
Table 1: 1057 patients were in the DMF group (59.7%) versus 713 in the TRF group
(40.3%). Approximately 39% of patients (40% in the DMF group versus 38% in the
TRF group) had at least one relapse during the follow-up.
We presented the confounder-adjusted results in the left panel of the Figure 5. The
GC and the IPW were equally robust to the considered set of covariates. For the differ-
ence of RMST, the width of the 95% CI was lower for the GC. For instance, when we
considered all the risk factors, GC led to a width of 44.2 days versus 50.9 days for IPW.
The conclusion of no significant difference between TRF and DMF was unaffected by
the method or the choice of the estimand.
4.2. Basiliximab versus Thymoglobulin to prevent post-transplant complications
Amongst the non-immunised kidney transplant recipients, one can expect similar rejec-
tion risk between Thymoglobulin (ATG) and Basiliximab (BSX), two possible immuno-
suppressive drugs proposed as induction therapy. However, the ATG may be associated
with higher serious events, especially in the elderly. We aimed to reanalysed the differ-
ence in cardiovascular complications in ATG versus BSX patients (Masset et al., 2019).
Table 2 describes the 383 included patients from the multicentric DIVAT cohort: 204
patients were in the BSX group (53.3%) versus 179 in the ATG group (46.7%). Approx-
imately 30% of patients (29% in the BSX group and 31% in the ATG group) had a least
one cardiovascular complication during the follow-up. The median follow-up time was
1.8 years (min: 0.0; max: 8.2).
We presented in the right panel of the Figure 5 the confounder-adjusted RMST
differences for a cohort followed up to 3 years. Firstly, the GC-based results obtained
were slightly less sensitive than those obtained by the IPW to the considered set of
covariates. Indeed, GC resulted in a ∆ˆ(3) equal to 2.6 (IC 95% from -1.2 to 7.0) and 4.0
(IC 95% from 0.2 to 8.5) months with all the risk factors and only the true confounders,
respectively. In contrast, the IPW resulted in a ∆ˆ(3) equal to 1.5 (IC 95% from -2.5 to
5.8) and 3.4 (IC 95% from -0.5 to 7.9) months, respectively. Likewise, the log of ÂHR
obtained by GC was in-between -0.272 (IC 95% from -0.703 to 0.123) and -0.440 (IC
95% from -0.898 to -0.021) versus -0.188 (IC 95% from -0.639 to 0.226) and -0.384 (IC
8 Chatton et al.
95% from -0.830 to 0.002) by IPW. This variability of the estimations, according to the
set of covariates, illustrates the importance of this choice. Secondly, we obtained the
smallest 95% CIs by using the GC with all the risk factors, in line with the corresponding
lower variance previously reported in the simulations. Thirdly, the conclusion differed
depending on the method: the IPW-based results did not point to a significant difference
of effect between BSX and ATG, in contrast to the GC with the true confounders.
5. Discussion
We aimed to explain and compare the performances of the GC and the IPW for estimat-
ing causal effects in time-to-event analyses with time-invariant confounders. We focused
on the average HR and the RMST difference. The results of the simulations showed that
the two methods performed similarly in terms of MAB, VEB, coverage rate, and type
I error rate. Nevertheless, the GC outperformed the IPW in terms of statistical power,
even when the censoring rate was high. Furthermore, the simulations also showed that
the Q-model in the GC approach should preferentially include all the risk factors to
ensure the smaller mean bias. Therefore, we reported that the main advantage of using
the GC is the gain in statistical power.
In the two applications, the 95% CIs were also narrower by using the GC with all the
risk factors. Moreover, while the first application in multiple sclerosis did not highlight
relevant differences between the GC and the IPW, the second one in kidney transplan-
tation illustrated the importance of the set of covariates to consider. By using the GC
with all the risk factors, we concluded to the significant difference between Basiliximab
and Thymoglobulin. In contrast, by using the GC with the true confounders, we re-
ported a non-significant difference. Two arguments can explain that the consideration
in the Q-model of all the risk factors was associated with the best performances. First,
it reduces the residual variance and increases the precision of the predictions of the po-
tential outcomes. Second, even if a risk factor is balanced between the exposure groups
at baseline, it could become unbalanced over time (as illustrated in Figure 1).
Nevertheless, the higher power of the GC can be counterbalanced by the inability
of GC to evaluate the characteristics balance between exposure group over time and
need for bootstrapping to estimate the variance, analytic estimators being available for
the IPW (Conner et al., 2019; Hajage et al., 2018). In practice, we must emphasise
that bootstrapping the entire estimation procedure, has the advantage to consider a
valid post-selection inference (Efron, 2014). For instance, data-driven methods for vari-
ables selection have recently been developed, such as the super learner (van der Laan
et al., 2007), and may represent a promising perspective when such clinical knowledge
is unavailable (Blakely et al., 2019).
The IPW and the GC are not the only possible methods to estimate the causal effect.
For instance, Conner et al. (2019) compared IPW performances with other regression-
based methods. Overall, the statistical performances were similar. However, the straight
advantage of the IPW and the GC compared to other methods is the visualisation
of the confounder-adjusted results in terms of survival curve or derivative indicator
such as RMST. The use of Doubly Robust Estimators (DREs) (Benkeser et al., 2018;
Cai and van der Laan, 2019) could be an extension of our work. The DREs combine
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both the PS and the GC approaches for a consistent estimation of the exposure effect
if a least one model has been correctly specified, circumventing the potential model
misspecification aforementioned (Lendle et al., 2013). Unfortunately, DREs can increase
bias when the two models are misspecified (Kang and Schafer, 2007). Moreover, several
studies reported a lower variance for the GC than the DREs (Chatton et al., 2020; Kang
and Schafer, 2007; Lendle et al., 2013). The use of the GC also represents a partial
solution to prevent the selection of instrumental variables (Myers et al., 2011) since it is
independent of the exposure modelling.
Our study has several limitations. Firstly, we only studied logistic and Cox PH re-
gression, but other models could be used. Keil and Edwards (2018) proposed a review
of possible Q-model with a time-to-event outcome. Secondly, the results of the simula-
tions and applications are not a theoretical argument for generalising to all situations.
Thirdly, we only considered a reduced number of covariates, which could explain the
equivalence mentioned above between the GC and the IPW with the extreme censoring
rate. Lastly, we did not consider competing events or time-varying confounders that
require specific estimation methods (Young et al., 2020; Daniel et al., 2013).
To conclude, the present study illustrates the higher power of the G-computation
compared to the inverse probability weighting to estimate the causal effect with time-to-
event outcomes. All the risk factors should be considered in the Q-model (except those
on the causal pathway). Our work is in the continuity of the emerging literature that
questions the near-exclusivity of propensity score-based methods in causal inference.
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Fig. 1. Distribution of a covariate L1 over time according to the exposure status in a simulated
population of one million people. L1 is moderately associated (OR = 1.3) with the outcome
under the alternative hypothesis.
Fig. 2. Causal diagram showing the covariates-outcome and the covariates-exposure
relationships.
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